Endocrinology Advisor2d
Enhertu Approved for HR+, HER2-Low/Ultralow Metastatic Breast Cancer
Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.
Targeted Oncology2d
The Targeted Pulse: The FDA Grants MB-105 ODD, and AI Helps Distinguish HER2 0 From 1+ in Breast Cancer
The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.
precisionmedicineonline4d
AstraZeneca Optimistic About Phase III Camizestrant Data in 2025, Reports Strong Q4 Product Growth
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.
STAT4d
Pharmalittle: We’re reading about a China probe of AstraZeneca, a ‘troubling’ Super Bowl ad, and more
A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super ...
verywellhealth5d
A New 'Missile' Drug Is Approved To Treat the Most Common Breast Cancer Type
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
Targeted Oncology6d
FDA Expands PATHWAY HER2 (4B5) Test to Include HER2-Ultralow Status
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
oncnursingnews6d
T-DXd Companion Diagnostic in HER2-Ultralow Metastatic Breast Cancer Gains FDA Approval
The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.